Last updated: 2026-09-05 17:39:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
NeuroSense Therapeutics Ltd. (NRSN) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $0.52, with a market capitalisation of $15.51M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.25 to $1.98. This page covers its latest market performance, valuation, price trends and company information.
$15.51M | |
$0.40 | |
$8.18 | |
$0.25 | |
$0.40 | |
4.00M | |
-- | |
-- | |
$1.98 | |
$0.25 | |
-- | |
-- |
NeuroSense Therapeutics Ltd. (NRSN) last closed at $0.40 as of 2026-09-05 00:00:00, unchanged from the previous close of $0.40.
During the latest regular trading session, NRSN traded between $0.25 and $8.18, with a volume of 4.00M shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, NeuroSense Therapeutics Ltd. (NRSN) moved from $0.45 to $0.52, representing a gain of 14.89% ($0.07).
The stock traded between $0.37 and $0.52 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 703.53 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 15.4%
NRSN is currently trading at $0.52, placing it 15.4% of the way from its 52-week low of $0.25 to its 52-week high of $1.98. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
| Employees | 16 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of NeuroSense Therapeutics Ltd. (NRSN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.